Overview
Eikon Therapeutics develops medicines by studying living cells with advanced engineering and data science. Its SMT platform visualizes protein motion in real time, while AI and automated workflows analyze these movements to map molecular interactions and identify drug targets. The company blends data science, chemistry, biology, engineering, and clinical expertise to inventory dynamic cellular processes at high scale, rather than relying on static snapshots. Its goal is to create therapies that improve and extend patients’ lives by targeting dynamic protein interactions inside cells.
Work here?Claim your company
About Eikon Therapeutics
Industries
Company Size
201-500
Company Stage
IPO
Headquarters
Millbrae, CA
Founded
2019
Get referred to Eikon Therapeutics
See people who can refer or advise you
Simplify's take
What believers are saying
- October 2026 ESMO data showed 63.1% ORR for EIK1001 across 65 evaluable patients.
- August 2026 melanoma DMC selected one EIK1001 dose, keeping TeLuRide-006 on track.
- June 2026 cash of $531.2 million funds operations into second-half 2027.
What critics are saying
- Eikon burned $88.4 million in Q2 2026 and still lacks product revenue.
- TeLuRide-005’s 2026 response data remain nonrandomized, and FDA still needs randomized proof.
- EIK1001’s systemic TLR7/8 activation carries cytokine-release risk across registrational trials.
What makes Eikon Therapeutics unique
- Roger Perlmutter’s team pairs live-cell single-molecule tracking with oncology drug discovery.
- EIK1001’s outpatient cytokine-managed dosing differentiates it from older TLR7/8 agonists.
- EIK1003 and EIK1004 target PARP1 selectivity; EIK1005 extends the platform into WRN biology.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1.5B
Above
Industry Average
Funded Over
5 Rounds
Benefits
- 401(k) Company Match
- Medical (premiums covered by Eikon at 95%)
- Dental Insurance
- Vision Insurance
- Mental Health Support
- Unlimited Paid Time Off
- Paid Holidays
- Life Insurance
- Enhanced Parental Leave
- Daily subsidized lunch program
Stock Price
Growth & Insights and Company News
6 month growth
2%1 year growth
0%2 year growth
0%Eikon Therapeutics eyes 2027 melanoma trial update, with key cancer data expected in 2029. Eikon Therapeutics (NASDAQ:EIKN) expects an interim analysis of its lead melanoma study in the first half of 2027 and estimates that definitive data from that trial and a lung cancer study could be available around the middle of 2029, CEO Roger Perlmutter said during a JPMorgan biotech call. Both studies are testing EIK1001, an experimental immune-stimulating drug, alongside standard cancer treatments. Perlmutter cautioned that the timing of the analyses depends on events such as disease progression, and that the company remains blinded to results by treatment group. Eikon has roughly 1,000 patients enrolled across oncology trials, Perlmutter said. He expects additional data over the next six to 12 months from programs spanning melanoma, lung, breast, ovarian and prostate cancers, as well as tumors with defects in DNA repair. Lead cancer trials advance. EIK1001 activates the toll-like receptors TLR7 and TLR8, an approach intended to stimulate an immune response against tumors. The registration-enabling melanoma and non-small cell lung cancer studies compare the drug plus standard care with placebo plus standard care. Perlmutter said the melanoma study has advanced further. An independent monitoring committee recommended a dose of 0.6 milligrams per square meter after comparing it with a higher dose. The next interim analysis will assess whether the study should proceed into its larger phase 3 portion; it is not powered to establish a treatment effect, he said. The lung cancer trial will undergo a dose-selection step followed by an event-driven analysis. Perlmutter said he expects the two programs to reach definitive results at roughly the same time, although the 2029 estimate is uncertain. Eikon presented mature phase 2 data at the ESMO cancer meeting for patients with squamous non-small cell lung cancer who received EIK1001 with Merck's Keytruda and chemotherapy. Perlmutter said the results showed a higher-than-expected response rate and lengthy responses, but emphasized that the single-arm study cannot be directly compared with other trials. He said the Food and Drug Administration agreed that the data supported a registration-enabling trial and told Eikon to request an accelerated approval evaluation if similar response and duration results appear in the randomized study. That possibility depends on future data; Perlmutter said randomized results are needed to establish whether EIK1001 improves outcomes. Systemic activation of TLR7 and TLR8 can cause cytokine release syndrome, a potentially serious inflammatory reaction. Perlmutter said Eikon has treated more than 600 patients with EIK1001 and uses body-surface-area dosing, among other measures, to manage the risk. He described the observed rate of grade 1 or 2 cytokine release syndrome as being in the single digits. PARP program targets combination use. Eikon is also developing two selective PARP1 inhibitors, EIK1003 and EIK1004. Perlmutter said the company designed the program around preclinical evidence that inhibiting the related PARP2 enzyme contributes to blood-cell toxicity seen with existing PARP inhibitors, though he cautioned that the mechanism has not been established in humans. Among the first 68 patients whose EIK1004 data were presented at ESMO, one had grade 3 anemia, he said. He reported a single-digit rate for EIK1003 and said the drugs' tolerability could allow them to be combined with chemotherapy earlier in treatment. Eikon presented EIK1003 data in combination with paclitaxel in previously treated patients. Perlmutter said the majority had either tumor responses or stable disease. He also cited a roughly 15% transfusion rate in a study combining EIK1003 with abiraterone in heavily pretreated prostate cancer patients. The company has begun studying EIK1003 with platinum chemotherapy and a taxane, a combination that could support first-line use. Perlmutter said Eikon is considering several registration opportunities and has not made a final decision, although a maintenance-therapy study is unlikely to be its first priority because it could take longer to produce results. EIK1004, which is designed to penetrate the central nervous system, may be of particular interest in patients prone to brain metastases, he said. Earlier-Stage pipeline. Perlmutter also discussed an experimental Werner helicase inhibitor developed using Eikon's microscopy platform. In initial data from 10 cancer patients, all six with microsatellite-unstable tumors had stable disease on the drug, he said. A separate patient receiving the drug with Keytruda had a partial response. He stressed that the findings were early and did not establish efficacy. Eikon has also filed an investigational new drug application for EIK1006, an experimental androgen receptor antagonist, and expects to begin enrolling patients soon, Perlmutter said. About Eikon Therapeutics (NASDAQ:EIKN). Eikon Therapeutics is a biotechnology company focused on discovering and developing medicines by combining advanced live-cell imaging with computational and biological research. Its technology platform is designed to observe the behavior of individual proteins in living cells, helping researchers investigate disease mechanisms and identify potential therapeutic targets. The company applies this platform to drug discovery and development, with an emphasis on oncology and other serious diseases.
Eikon Therapeutics reported second quarter 2026 financial results and clinical updates across its oncology pipeline. The company had $531.2 million in cash, cash equivalents and marketable securities as of 30 June 2026, expected to fund operations into the second half of 2027. Seven abstracts were accepted for presentation at the European Society for Medical Oncology Congress 2026, covering clinical candidates EIK1001, EIK1003, EIK1004 and EIK1005. The company progressed its TeLuRide-006 Phase 2/3 registrational trial of EIK1001 through a first interim analysis for first-line advanced melanoma treatment. Net loss attributable to common stockholders was $88.4 million for the second quarter of 2026, compared to $105.2 million in the prior-year period. Research and development expenses increased 9% to $75.5 million, whilst general and administrative expenses decreased 56% to $17.9 million.
Eikon Therapeutics has appointed Ma. Fatima Francisco as an independent director to its board, effective 15 June 2026. Francisco will also serve on the board's Compensation Committee. Francisco most recently served as chief executive officer of Baby, Feminine and Family Care at Procter & Gamble, where she led one of the company's largest global business units during a career spanning over 35 years. She currently serves on the boards of HP Inc. and Nestlé, and previously served on Organon's board. Eikon is a late-stage clinical biopharmaceutical company focused on developing cancer treatments using its proprietary single molecule tracking system. The company combines traditional biology research with advanced engineering to develop novel therapies addressing unmet medical needs.
Eikon Therapeutics announces availability of six abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology. May. 21, 2026, 05:05 PM * Presentations to cover progress across Eikon's most advanced clinical-stage programs * Updated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lung cancer ("NSCLC"), EIK1003, as a monotherapy or in combination in the treatment of patients with breast, ovarian, prostate, or pancreatic cancer, and EIK1005, which is designed to improve treatment of patients whose tumors demonstrate certain DNA replication abnormalities. MILLBRAE, Calif., May 21, 2026 (GLOBE NEWSWIRE) - Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the publication of full-text abstracts from its lead programs to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago beginning on 29 May 2026. The six accepted presentations highlight clinical progress across Eikon's pipeline, including the TLR7 and TLR8 dual-agonist EIK1001 trials in NSCLC and advanced melanoma, updated data for its highly selective PARP1 inhibitor EIK1003, and early development progress for the WRN inhibitor candidate EIK1005. "We look forward to presenting these data at the ASCO Annual Meeting, which reflect the breadth of our oncology pipeline and our focus on advancing novel therapeutic approaches across multiple mechanisms and treatment settings," said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon. "Our programs are evaluating both monotherapy and combination strategies in patients with advanced disease, with the goal of generating insights that can inform patient selection, optimize treatment approaches, and ultimately support future registration of these novel therapeutics." 2026 ASCO Abstract Titles and Presentation Details: Title: Efficacy, safety and cytokine profiling with addition of the toll-like receptor (TLR) 7/8 dual agonist EIK1001 to Standard of Care First-Line Therapy: the Phase 2 TeLuRide-005 trial in Stage 4 Non-Small Cell Lung Cancer Title: Adaptive Phase 2/3 Study of EIK1001, a TLR7/8 Dual Agonist, in Combination with Pembrolizumab, as First-Line Therapy in Participants with Advanced Melanoma (TeLuRide-006) Title: A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008) Title: EIK1003, a PARP1-selective inhibitor, in combination with paclitaxel (PTX): Initial combination and updated monotherapy results from a Phase 1/2 study EIK1003-001 in advanced solid tumors Title: First-in-Human Study to Evaluate the Safety, Tolerability, and PK of EIK1005, a Novel WRN Inhibitor in Healthy Participants Title: Phase 1/2 Study of the novel Werner helicase inhibitor EIK1005 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors, including MSI-H or dMMR Tumors About Eikon Therapeutics Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing innovative medicines to address serious unmet medical needs. Eikon's initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally-derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon's vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit www.eikontx.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential of Eikon's product candidates; the timing for anticipated data readouts; expected milestones and business objectives for 2026 and beyond, including Eikon's anticipated presentations at the ASCO Annual Meeting; and other statements regarding Eikon's future operations, financial performance, financial position, prospects, objectives, strategies and other future events. These forward-looking statements are based upon management's current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption "Risk Factors" and elsewhere in Eikon's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission ("SEC") on May 11, 2026, and in other public filings with the SEC in the future. As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law. Investors Alfred "Freddie" Bowie, Ph.D., CFO [email protected] Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post. Sponsored Financial Content Five-star memories in Punta Cana.Not all memories feel the same. At Grand Palladium Hotels & Resorts, yours include waking up to the Caribbean Sea, dining under the stars, and the privilege of having everything taken care ofPalladium Hotel Group | Sponsored
Eikon Therapeutics announces availability of six abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology. GlobeNewswire | Eikon Therapeutics, Inc. Today at 2:05pm PDT * Presentations to cover progress across Eikon's most advanced clinical-stage programs * Updated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lung cancer ("NSCLC"), EIK1003, as a monotherapy or in combination in the treatment of patients with breast, ovarian, prostate, or pancreatic cancer, and EIK1005, which is designed to improve treatment of patients whose tumors demonstrate certain DNA replication abnormalities. MILLBRAE, Calif., May 21, 2026 (GLOBE NEWSWIRE) - Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the publication of full-text abstracts from its lead programs to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago beginning on 29 May 2026. The six accepted presentations highlight clinical progress across Eikon's pipeline, including the TLR7 and TLR8 dual-agonist EIK1001 trials in NSCLC and advanced melanoma, updated data for its highly selective PARP1 inhibitor EIK1003, and early development progress for the WRN inhibitor candidate EIK1005. "We look forward to presenting these data at the ASCO Annual Meeting, which reflect the breadth of our oncology pipeline and our focus on advancing novel therapeutic approaches across multiple mechanisms and treatment settings," said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon. "Our programs are evaluating both monotherapy and combination strategies in patients with advanced disease, with the goal of generating insights that can inform patient selection, optimize treatment approaches, and ultimately support future registration of these novel therapeutics." 2026 ASCO Abstract Titles and Presentation Details: Title: Efficacy, safety and cytokine profiling with addition of the toll-like receptor (TLR) 7/8 dual agonist EIK1001 to Standard of Care First-Line Therapy: the Phase 2 TeLuRide-005 trial in Stage 4 Non-Small Cell Lung Cancer Title: Adaptive Phase 2/3 Study of EIK1001, a TLR7/8 Dual Agonist, in Combination with Pembrolizumab, as First-Line Therapy in Participants with Advanced Melanoma (TeLuRide-006) Title: A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008) Title: EIK1003, a PARP1-selective inhibitor, in combination with paclitaxel (PTX): Initial combination and updated monotherapy results from a Phase 1/2 study EIK1003-001 in advanced solid tumors Title: First-in-Human Study to Evaluate the Safety, Tolerability, and PK of EIK1005, a Novel WRN Inhibitor in Healthy Participants Title: Phase 1/2 Study of the novel Werner helicase inhibitor EIK1005 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors, including MSI-H or dMMR Tumors About Eikon Therapeutics Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing innovative medicines to address serious unmet medical needs. Eikon's initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally-derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon's vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit www.eikontx.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential of Eikon's product candidates; the timing for anticipated data readouts; expected milestones and business objectives for 2026 and beyond, including Eikon's anticipated presentations at the ASCO Annual Meeting; and other statements regarding Eikon's future operations, financial performance, financial position, prospects, objectives, strategies and other future events. These forward-looking statements are based upon management's current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption "Risk Factors" and elsewhere in Eikon's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission ("SEC") on May 11, 2026, and in other public filings with the SEC in the future. As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law. Investors Alfred "Freddie" Bowie, Ph.D., CFO [email protected] This is a paid placement. For further inquiries, please contact GlobeNewswire directly.
Eikon Therapeutics is Hiring for 13 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
About Eikon Therapeutics
Industries
Company Size
201-500
Company Stage
IPO
Headquarters
Millbrae, CA
Founded
2019
Eikon Therapeutics is Hiring for 13 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs